Site icon fundsforNGOs

US: Ryan White HIV/AIDS Program AIDS Drug Assistance Program – Emergency Relief Fund

Deadline: 03-Nov-2025

The U.S. Health Resources and Services Administration (HRSA) has announced the availability of funding under the Ryan White HIV/AIDS Program (RWHAP) Part B AIDS Drug Assistance Program (ADAP) Emergency Relief Funds (ERF).

This initiative aims to ensure that people living with HIV continue to receive uninterrupted access to life-saving medications and health care coverage, particularly in states and territories facing financial shortfalls or surges in treatment demand.

The ADAP ERF program provides critical financial support to states and territories to prevent, reduce, or eliminate waiting lists for HIV medication assistance and to address funding gaps that could limit access to essential care. These funds complement the regular RWHAP Part B ADAP base award and are allocated based on demonstrated need. HRSA’s goal is to strengthen the national HIV response by helping jurisdictions maintain continuity in treatment and advance progress toward ending the HIV epidemic in the United States.

At the time of the announcement, no ADAP waiting lists exist; however, jurisdictions that experience new waiting lists must report them immediately and use the awarded funds to ensure that clients receive timely access to medication. HRSA also anticipates a potential rise in demand for ADAP services due to factors such as loss of healthcare coverage, reduced program income, and increased case identification. States and territories may use ERF resources to respond to these pressures and maintain equitable access to treatment for all eligible individuals.

For fiscal year 2026, HRSA expects to distribute up to $75 million across approximately 25 awards, with grants ranging from $100,000 to $10 million depending on the level of need. States with active waiting lists may apply for up to $10 million, while those without waiting lists may apply for up to $7 million. The grant period will run for twelve months, from April 1, 2026, through March 31, 2027, with awards subject to available federal appropriations.

Eligible applicants include state governments, U.S. territories, and freely associated states that currently receive RWHAP Part B funding and can demonstrate a need for additional resources. Applicants must use the funding to address existing or potential waiting lists, compensate for reduced funding, or manage increased demand resulting from new diagnoses, re-engagement in care, or loss of income or coverage.

Through this funding opportunity, HRSA reaffirms its commitment to ensuring that financial constraints never become a barrier to HIV treatment access, empowering states and territories to strengthen their ADAP programs and safeguard the health and well-being of people living with HIV across the United States and its territories.

For more information, visit Grants.gov.

Exit mobile version